Placebo + Zoledronic acid
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Post-menopausal Osteoporosis
Conditions
Post-menopausal Osteoporosis
Trial Timeline
May 1, 2008 → Apr 1, 2013
NCT ID
NCT00718861About Placebo + Zoledronic acid
Placebo + Zoledronic acid is a phase 3 stage product being developed by Novartis for Post-menopausal Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00718861. Target conditions include Post-menopausal Osteoporosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00718861 | Phase 3 | Completed |
| NCT00639392 | Phase 1/2 | Withdrawn |
Competing Products
19 competing products in Post-menopausal Osteoporosis